COVID-19 - July 14, 2021
Encouraging results from BerGenBio
BerGenBio has presented a combined analysis of data from two Phase II studies investigating bemcentinib in hospitalised COVID-19 patients. Data was presented from the UKRI PhaseII ACCORD2 platform study, sponsored by University Hospital Southampton, UK and BGBC020, BerGenBio’s open-label Phase II study conducted in South Africa and India. In total, 179 eligible patients were enrolled […]
Pharma Business - June 9, 2021
BerGenBio receives Fast Track designation
BerGenBio has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for bemcentinib in combination with an anti-PD-(L)1 agent for the treatment of patients with AXL-positive advanced/metastatic non-small cell lung cancer (NSCLC). The FDA’s decision represents the first recognition by a regulator of AXL-positive patients as a molecular targetable patient […]
COVID-19 - May 26, 2021
New trial data about BerGenBio’s bemcentinib in COVID-19 patients
The company has announced data from a Phase II trial assessing Bemcentinib in hospitalized COVID-19 patients. The trial shows that Bemcentinib has the potential to increase the rate of ventilator free survival in more than 50% of hospitalized COVID-19 patients, states the company in a press release. The trial was conducted from October 2020 across multiple […]
Clinical Trials - April 30, 2020
BerGenBio’s Bemcentinib – potential treatment for COVID-19
BerGenBio has announced that bemcentinib has been selected as the first potential treatment to be fast-tracked in a new UK national multi-centre randomized Phase II clinical trial initiative. The ACcelerating COVID-19 Research & Development platform (ACCORD) study is being funded by the Department of Health and Social Care (DHSC) and UK Research and Innovation (UKRI). […]
Business article - February 24, 2020
Q&A: Richard Godfrey, CEO of BerGenBio
It is an exciting year for BerGenBio and its AXL inhibitor. Upcoming trial data will define their way forward towards a new approach to fighting cancer and improving the efficacy of cancer treatments. The Norwegian clinical stage biopharmaceutical company BerGenBio, founded in 2007, is based on identification and understanding of the protein AXL kinase. This […]
Clinical Trials - January 7, 2020
BerGenBio presents preliminary clinical data
BerGenBio has provided an update from the company’s phase II study of bemcentinib (BGB324), an oral AXL inhibitor, in combination with low-dose cytarabine (LDAC) in elderly AML patients. The bemcentinib-LDAC combination was safe and well tolerated in elderly AML patients and showed promising efficacy among both newly diagnosed and relapsed/refractory AML patients. The overall response […]
